SMS Pharmaceuticals earnings calls.

SMS Pharmaceuticals delivered solid FY26 results with 13Current reported value: 13. No comparable prior figure is available in the source record.% revenue growth to Rs 887 crore and 23% EBITDA growth to Rs 171Current reported value: 171. No comparable prior figure is available in the source record. crore, with margins expanding to 20%. Q4 standalone PAT of Rs 21 crore (including Rs 12 crore from associate BKD Pharma) beat year-ago levels. The EBITDA margin improvement reflects benefits from backward integration, favorable product mix, and operating leverage. Gross margin contracted quarter-on-quarter due to rising solvent costs from Middle East geopolitical tensions. Management guides conservatively for 15% revenue growth in FY27 while targeting 22%+ EBITDA margins, with upside potential to 20-25% growth if external conditions stabilize. The 280 crore brownfield expansion (130 crore already invested) to increase capacity to 800 MT/monthCurrent 800 MT/month. Reported change: +60% (from 500 MT). remains on track for FY27 completion with revenue impact from FY28. Key risks include customer concentration (28Current reported value: 28. No comparable prior figure is available in the source record.% from top customer), export-heavy business (70% currently, moving to 75%), and geopolitical supply chain volatility affecting raw material costs. Peptides and CMO initiatives remain medium-term opportunities with clarity expected in 2 quarters.